GlycoMimetics Announces High Overall Response Rates, Low Induction Mortality, Promising Initial Survival Outcomes, and Supportive Biomarker Data from Phase 1/2 Trial of GMI-1271 in AML

Stock Information for GlycoMimetics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About GlycoMimetics Inc.

GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024
GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.